Oral immunization of mice with Lactococcus lactis expressing Shiga toxin truncate confers enhanced protection against Shiga toxins of Escherichia coli O157:H7 and Shigella dysenteriae.
Administration, Oral
Animals
Antibodies, Bacterial
/ administration & dosage
Antibodies, Neutralizing
/ administration & dosage
Antitoxins
/ administration & dosage
Bacterial Vaccines
/ administration & dosage
Cell Survival
/ drug effects
Disease Models, Animal
Drug Carriers
/ administration & dosage
Escherichia coli O157
/ genetics
Genetic Vectors
/ administration & dosage
HeLa Cells
Humans
Lactococcus lactis
/ genetics
Mice
Mice, Inbred BALB C
Poisoning
/ prevention & control
Shiga Toxin
/ genetics
Shigella dysenteriae
/ genetics
Survival Analysis
Treatment Outcome
Vaccines, Synthetic
/ administration & dosage
Lactococcus lactis
LL-Stx2a1
Shiga toxin (Stx)
oral vaccine
toxin neutralization
Journal
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
ISSN: 1600-0463
Titre abrégé: APMIS
Pays: Denmark
ID NLM: 8803400
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
27
02
2019
accepted:
11
07
2019
pubmed:
26
7
2019
medline:
19
9
2019
entrez:
26
7
2019
Statut:
ppublish
Résumé
Regardless of the communal impact of Shiga toxins, till today neither a specific treatment nor licensed vaccine is available. Lactococcus lactis (L. lactis), generally regarded as safe organism, is well known to provide a valuable approach regarding the oral delivery of vaccines. This study was undertaken to evaluate the protective efficacy of Stx2a1 expressed in nisin-inducible L. lactis, against Shiga toxins (Stx1, Stx2) in mouse model. Oral immunization of BALB/c mice with LL-Stx2a1 elicited significant serum antibody titer with elevated fecal and serum IgA, along with minimized intestinal and kidney damage resulting in survival of immunized animals at 84% and 100% when challenged with 10 × LD
Substances chimiques
Antibodies, Bacterial
0
Antibodies, Neutralizing
0
Antitoxins
0
Bacterial Vaccines
0
Drug Carriers
0
Vaccines, Synthetic
0
Shiga Toxin
75757-64-1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
671-680Subventions
Organisme : Research and Development
Informations de copyright
© 2019 APMIS. Published by John Wiley & Sons Ltd.
Références
Taylor CM. Enterohaemorrhagic Escherichia coli and Shigella dysenteriae type 1-induced haemolytic uraemic syndrome. Pediatr Nephrol 2008;23:1425-31.
Bitzan M. Treatment options for HUS secondary to Escherichia coli O157: H7. Kidney Int 2009;75:62-6.
Walsh PR, Johnson S. Treatment and management of children with haemolytic uraemic syndrome. Arch Dis Child 2018;103:285-91.
Keir LS. Shiga toxin associated hemolytic uremic syndrome. Hematol Oncol Clin 2015;29:525-39.
O'Brien AD, Holmes RK. Shiga and Shiga-like toxins. Microbiol Rev 1987;51:206.
Paton JC, Paton AW. Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections. Clin Microbiol Rev 1998;11:450-79.
Siegler RL. The hemolytic uremic syndrome. Pediatr Clin North Am 1995;42:1505-29.
Inward CD, Howie AJ, Fitzpatrick MM, Rafaat F, Milford DV, Taylor CM. Taylor Renal histopathology in fatal cases of diarrhoea-associated haemolytic uraemic syndrome. Pediatr Nephrol 1997;11:556-9.
Taguchi T, Uchida H, Kiyokawa N, Mori T, Sato N, Horie H, et al. Verotoxins induce apoptosis in human renal tubular epithelium derived cells. Kidney Int 1998;53:1681-8.
Melton-Celsa AR. Shiga toxin (Stx) classification, structure, and function. Microbiol Spectr 2014;2:1-21.
Zhang W, Bielaszewska M, Kuczius T, Karch H. Identification, characterization, and distribution of a Shiga toxin 1 gene variant (stx1c) in Escherichia coli strains isolated from humans. J Clin Microbiol 2002;40:1441-6.
Kuczius T, Bielaszewska M, Friedrich AW, Zhang W. A rapid method for the discrimination of genes encoding classical Shiga toxin (Stx) 1 and its variants, Stx1c and Stx1d, in Escherichia coli. Mol Nutr Food Res 2004;48:515-21.
Lingwood CA, Binnington B, Manis A, Branch DR. Globotriaosyl ceramide receptor function-where membrane structure and pathology intersect. FEBS Lett 2010;584:1879-86.
Keir LS, Marks SD, Kim JJ. Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies. Drug Des Devel Ther 2012;6:195.
Bielaszewska M, Idelevich EA, Zhang W, Bauwens A, Schaumburg F, Mellmann A, et al. Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction by epidemic Escherichia coli O104: H4 strain. Antimicrob Agents Chemother 2012;56:3277-82.
Tzipori S, Sheoran A, Akiyoshi D, Donohue-Rolfe A, Trachtman H. Antibody therapy in the management of Shiga toxin-induced hemolytic uremic syndrome. Clin Microbiol Rev 2004;17:926-41.
Nishikawa K. Recent progress of Shiga toxin neutralizer for treatment of infections by Shiga toxin-producing Escherichia coli. Arch Immunol Ther Exp 2011;59:239-47.
Rahal EA, Fadlallah SM, Nassar FJ, Kazzi N, Matar GM. Approaches to treatment of emerging Shiga toxin-producing Escherichia coli infections highlighting the O104: H4 serotype. Front Cell Infect Microbiol 2015;5:24.
Demberg T, Robert-Guroff M. Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design. Int Rev Immunol 2009;28:20-48.
Pavot V, Rochereau N, Genin C, Verrier B, Paul S. New insights in mucosal vaccine development. Vaccine 2012;30:142-54.
Bermudez-Humaran LG. Lactococcus lactis as a live vector for mucosal delivery of therapeutic proteins. Hum Vaccin Immunother 2009;5:264-7.
Lee MH, Roussel Y, Wilks M, Tabaqchali S. Expression of Helicobacter pylori urease subunit B gene in Lactococcus lactis MG1363 and its use as a vaccine delivery system against H. pylori infection in mice. Vaccine 2001;19:3927-35.
Azizpour M, Hosseini SD, Jafari P, Akbary N. Lactococcus lactis: A New Strategy for Vaccination. Avicenna J Med Biotechnol 2017;9:163.
Mierau I, Kleerebezem M. 10 years of the nisin-controlled gene expression system (NICE) in Lactococcus lactis. Appl Microbiol Biotechnol 2005;68:705-17.
Asensi GF, de Sales NF, Dutra FF, Feijo DF, Bozza MT, Ulrich RG, et al. Oral immunization with Lactococcus lactis secreting attenuated recombinant staphylococcal enterotoxin B induces a protective immune response in a murine model. Microb Cell Fact 2013;12:32.
Zadravec P, Mareckova L, Petrokova H, Hodnik V, Nanut MP, Anderluh G, et al. Development of recombinant Lactococcus lactis displaying albumin-binding domain variants against shiga toxin 1 B subunit. PLoS ONE 2016;11:e0162625.
Dutta S, Iida KI, Takade A, Meno Y, Nair GB, Yoshida SI. Release of Shiga toxin by membrane vesicles in Shigella dysenteriae serotype 1 strains and in vitro effects of antimicrobials on toxin production and release. Microbiol Immunol 2004;48:965-9.
Head SC, Petric M, Richardson S, Roscoe M, Karmali MA. Purification and characterization of verocytotoxin 2. FEMS Microbiol Lett 1988;51:211-5.
Ahmed B, Loos M, Vanrompay D, Cox E. Mucosal priming of the murine immune system against enterohemorrhagic Escherichia coli O157: H7 using Lactococcus lactis expressing the type III secretion system protein EspB. Vet Immunol Immunopathol 2013;152:141-5.
Fischinger S, Boudreau CM, Butler AL, Streeck H, Alter G. Sex differences in vaccine-induced humoral immunity. Semin immunopathol 2019;41:239-49.
Reddy PN, Paul S, Sripathy MH, Batra HV. Evaluation of recombinant SEA-TSST fusion toxoid for protection against superantigen induced toxicity in mouse model. Toxicon 2015;103:106-13.
Tu W, Li T, Wang Q, Cai K, Gao X, Wang H. A simple method for expression and purification of Shiga toxin 1 (Stx1) with biological activities by using a single-promoter vector and native signal peptide. Biotechnol Appl Biochem 2016;63:539-45.
Cai K, Gao X, Li T, Wang Q, Hou X, Tu W, et al. Enhanced immunogenicity of a novel Stx2Am-Stx1B fusion protein in a mice model of enterohemorrhagic Escherichia coli O157: H7 infection. Vaccine 2011;29:946-52.
Liu L, Zeng H, Luo P, Wu J, Chen H, Shi Y, et al. Cloning a truncated fragment (stx2a 1) of the Shiga-like Toxin 2A 1 subunit of EHEC O157: H7: candidate immunogen for a subunit vaccine. Mol Biotechnol 2009;43:8.
Villena J, Medina M, Raya R, Alvarez S. Oral immunization with recombinant Lactococcus lactis confers protection against respiratory pneumococcal infection. Can J Microbiol 2008;54:845-53.
Saez D, Fernandez P, Rivera A, Andrews E, Onate A. Oral immunization of mice with recombinant Lactococcus lactis expressing Cu, Zn superoxide dismutase of Brucella abortus triggers protective immunity. Vaccine 2012;30:1283-90.
Ahmed B, Loos M, Vanrompay D, Cox E. Oral immunization with Lactococcus lactis-expressing EspB induces protective immune responses against Escherichia coli O157: H7 in a murine model of colonization. Vaccine 2014;32:3909-16.
Rottiers P, De Smedt T, Steidler L. Modulation of gut-associated lymphoid tissue functions with genetically modified Lactococcus lactis. Int Rev Immunol 2009;28:465-86.
Guo S, Yan W, McDonough SP, Lin N, Wu KJ, He H, et al. The recombinant Lactococcus lactis oral vaccine induces protection against C. difficile spore challenge in a mouse model. Vaccine 2015;33:1586-95.
TaghinezhadS S, Mohseni AH, Keyvani H, Razavilar V. Protection against human papillomavirus type 16-induced tumors in C57BL/6 mice by mucosal vaccination with Lactococcus lactis NZ9000 expressing E6 oncoprotein. Microb Pathog 2019;126:149-56.
Cheng Y, Feng Y, Luo P, Gu J, Yu S, Zhang WJ, et al. Fusion expression and immunogenicity of EHEC EspA-Stx2Al protein: implications for the vaccine development. J Microbiol 2009;47:498-505.
Wen SX, Teel LD, Judge NA, O'Brien AD. Genetic toxoids of Shiga toxin types 1 and 2 protect mice against homologous but not heterologous toxin challenge. Vaccine 2006;24:1142-8.
Smith MJ, Teel LD, Carvalho HM, Melton-Celsa AR, O'Brien AD. Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2. Vaccine 2006;24:4122-9.
Lynn RM, O'Brien SJ, Taylor CM, Adak GK, Chart H, Cheasty T, et al. Childhood hemolytic uremic syndrome, United Kingdom and Ireland. Emerg Infect Dis 2005;11:590.
Butler T. Haemolytic uraemic syndrome during shigellosis. Trans R Soc Trop Med Hyg 2012;106:395-9.
Adams C, Vose A, Edmond MB, Lyckholm L. Shigella sonnei and hemolytic uremic syndrome: A case report and literature review. IDCases 2017;8:6-8.